Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Breast Cancer Reports
Metadata
Title
Correction to: Ablative Treatment of Breast Cancer; Are We There Yet?
Author
David R Brenin
Publication date
01-06-2019
Publisher
Springer US
Published in
Current Breast Cancer Reports / Issue 2/2019
Print ISSN: 1943-4588
Electronic ISSN: 1943-4596
DOI
https://doi.org/10.1007/s12609-019-00313-7

Other articles of this Issue 2/2019

Current Breast Cancer Reports 2/2019 Go to the issue

Local-Regional Evaluation and Therapy (DM Euhus, Section Editor)

Practical Perspectives Regarding Patient Selection and Technical Considerations in Oncoplastic Surgery

Local-Regional Evaluation and Therapy (DM Euhus, Section Editor)

Role of Liquid Biopsy in Clinical Decision-Making for Breast Cancer

Local-Regional Evaluation and Therapy (DM Euhus, Section Editor)

Ablative Treatment of Breast Cancer; Are We There Yet?

Local-Regional Evaluation and Therapy (DM Euhus, Section Editor)

Surgical Therapy for Women with Multiple Synchronous Ipsilateral Breast Cancer (MIBC): Current Evidence to Guide Clinical Practice

Breast Cancer Imaging and Screening (N Sharma, Section Editor)

Management of B3 Lesions—Practical Issues

Breast Cancer Imaging and Screening (N Sharma, Section Editor)

Diffusion-Weighted Magnetic Resonance Imaging of the Breast: an Accurate Method for Measuring Early Response to Neoadjuvant Chemotherapy?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits